Recent Additions
  • Publication
    Microbiota in Health and Disease
  • BACKGROUND/OBJECTIVES: The 6-minute walking test (6MWT) is an easily performed, widely available and well-tolerated test for assessing the functional capacity of patients with HF in everyday clinical practice. The measurement properties of the 6MWT, such as reliability and validity, have been studied in patients with chronic heart failure, coronary artery disease, and cancer. However, little is currently known about the 6MWT and cardiotoxicity. The study was aimed at assessing the incidence of cancer therapy-related cardiovascular toxicity, identified the role of 6MWT as early predictor of early onset cardiotoxicity. METHODS: We performed a prospective study of 85 patients with breast cancer, treated with doxorubicin-based chemotherapy in the Department of Oncology and Hematology. 2D echocardiography and speckle tracking echocardiography were performed before anticancer treatment was started and after the treatment. We defined anthracycline-induced subclinical cardiotoxicity if a decline in global longitudinal strain (GLS) by >15% from baseline was observed and based on that patients were divided into two groups– patients with subclinical cardiotoxicity and patients without subclinical cardiotoxicity. The 6MWT was developed by the American Thoracic Society comprehensive guidelines. The 6MWT was performed in a long straight hospital corridor, over a 30-m distance. Statistical analysis was performed with „IBM SPSS statistics 27.0" program. Statistical significance level p<0.05. RESULTS: In the study population statistically significant GLS reduction was detected before and after the anticancer treatment (-21±0.53 vs. -18.1± 1.18, p<0.01). Of 85 women (mean age, 54.5 (9.3) years) subclinical left ventricle dysfunction was identified in 51 (60%). We found a significant negative correlation between baseline 6MWT and cardiotoxicity (r=0.3 and p=0.02). The baseline 6MWT results were significantly lower among patients with subclinical cardiotoxicity (494.3 ± 40.5 m vs 629.8 ± 60.1 m, p<0.001). The diagnostic validity of 6 MWT as a cardiotoxicity biomarker was evaluated using the non-parametric ROC curve (Pic. 1). We obtained an optimal cut-off point of 6MWT of ≤540m. (AUC=0.98; p < 0.001). CONCLUSIONS: Baseline 6MWT may be used as independed prognostic predictor of subclinical anthracycline-induced cardiotoxicity.
  • Researcher
    Jurkevičius, Justas
    Istorija / History
  • research article
    Hordiei, Karyna
    Gontova, Tetiana
    Yaremenko, Maksym
    Tanacetum parthenium, also known as feverfew, is rich in bioactive compounds, namely sesquiterpene lactones, flavonoids, and volatile oils. Sesquiterpene lactones possess anti-migraine activity, while phenolic compounds possess anti-inflammatory and antioxidant action. Phytochemical composition determines the pharmacological activity and so profiling is essential in quality assessment. The study aimed to evaluate cultivated feverfew plants’ phenolic profiles and antioxidant activity. Eleven phenolic compounds were identified in the samples of feverfew in Ukraine. Hydroxycinnamic acids predominate in the quantitative content of all the samples, namely chlorogenic acid, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid. The total content of flavonoids ranged from 0.8 to 2.6%; the content of hydroxycinnamic acids varied from 3.3 to 6.5%. The obtained data testify to the prospects of using Ukrainian feverfew as a raw material with a significant content of phenolic substances to develop new herbal medicines.
      3WOS© IF 4.5WOS© AIF 4.3Scopus© SNIP 1.277
  • conference poster not in proceedings; ;
    Glasgow : European Society of Human Genetics, 2023
    Background/Objectives: Treatment of mental disorders is often a complex and lengthy process. Based on the principles of personalized medicine, psychiatrists can tailor medications, dosages and combinations of medications according to pharmacogenetic test reports. We present clinical cases that demonstrate benefits and uncertainties of pharmacogenetic testing. Methods: Blood DNA extraction and pharmacogenetic testing were performed according to the manufacturers` protocols. Genes included in pharmacogenetic analysis: COMT,CYP2C9,CYP2C19,CYP2D6,MTHFR,CYP3A4,CYP3A5,CYP1A2,SLCO1B1,VKORC1. Results: Case no.1: young man with obsessive-compulsive disorder who has been unsuccessfully treated for eight years. The pharmacogenetic testing revealed an unusual phenotype. Treatment based on recommendations of prescribing guidelines was not effective for that patient. The patient is currently living an independent and socially active life while taking a treatment not indicated by the pharmacogenetic testing. Case no.2: young female with schizoaffective disorder, for whom all previously used psychotropic medications were discontinued due to reported adverse effects. After numerous unsuccessful treatment attempts, a pharmacogenetic testing was performed and showed a normal metabolizer phenotype for all psychotropic medications. The pharmacogenetic results led to an open conversation in which the patient admitted to be non adherence. Conclusion: There is still a lack of knowledge and data on the genes involved in drug metabolism and drug interactions. In the absence of sufficient information in treatment guidelines, the question is what to do when treatment fails? Further research is needed to identify other factors contributing to tolerance when a drug is not recommended on the basis of pharmacogenetic testing, or intolerance when a drug is recommended.
Most viewed
Most downloaded